Instituto Grifols, S.A. clinical trials

A subsidiary of Grifols

The registry lists 24 studies whose lead sponsor is Instituto Grifols, S.A.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 7, 2026.

Studies

Recruiting first, then most recently updated. Showing 24 of 24. All Grifols studies →

• Safety, Pharmacokinetics and Efficacy of an ATIII ConcentrateTerminatedNCT00319228Phase 2/3

  Sponsor listed in the registry: Instituto Grifols, S.A.

• Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).CompletedNCT07264517Phase 2

  Sponsor listed in the registry: Instituto Grifols, S.A.

• Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasma Exchange With Human Serum Albumin 5%TerminatedNCT03702920Phase 3

  Sponsor listed in the registry: Instituto Grifols, S.A.

• Study of the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma® 5% Dual Inactivation and Filtration (DIF) in Participants With Post-polio SyndromeTerminatedNCT02176863Phase 2/3

  Sponsor listed in the registry: Instituto Grifols, S.A.

• FIB Grifols Congenital Deficiency for On-demand Treatment and Surgical ProphylaxisWithdrawnNCT04636268Phase 3

  Sponsor listed in the registry: Instituto Grifols, S.A.

• A Study of Safety and Efficacy of Fibrin Sealant Grifols as an Adjunct to Haemostasis During Surgery in Paediatric ParticipantsCompletedNCT03461406Phase 3

  Sponsor listed in the registry: Instituto Grifols, S.A.

• Study to Evaluate the Safety and Efficacy of Prolastin in Hospitalized Subjects With COVID-19CompletedNCT04495101Phase 2

  Sponsor listed in the registry: Instituto Grifols, S.A.

• Study to Evaluate the Safety and Efficacy of High Dose IVIG in Hospitalized Participants With Coronavirus Disease (COVID-19)CompletedNCT04432324Phase 2

  Sponsor listed in the registry: Instituto Grifols, S.A.

• A Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19)CompletedNCT04547127Phase 2

  Sponsor listed in the registry: Instituto Grifols, S.A.

• Efficacy and Safety of Plasma Exchange With Albumin in Patients With Amyotrophic Lateral SclerosisCompletedNCT02479802Phase 2

  Sponsor listed in the registry: Instituto Grifols, S.A.

• A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's DiseaseCompletedNCT01561053Phase 2/3

  Sponsor listed in the registry: Instituto Grifols, S.A.

• Effects of Long Term Albumin 20% Administration in Patients With Cirrhosis and Ascites.CompletedNCT00968695Phase 4

  Sponsor listed in the registry: Instituto Grifols, S.A.

• Effects on Plasma Exchange on Functional Capacity of Serum Albumin, Circulatory Dysfunction, Renal and Cerebral Function in Cirrhotic Patients With "Acute-on-chronic Liver Failure"CompletedNCT01201720Not applicable

  Sponsor listed in the registry: Instituto Grifols, S.A.

• Safety and Efficacy of Topical Thrombin (Human) Grifols as an Adjunct to Hemostasis During SurgeryCompletedNCT02014402Phase 2

  Sponsor listed in the registry: Instituto Grifols, S.A.

• Safety and Efficacy Study of Fibrin Sealant Grifols as an Adjunct to Hemostasis During Peripheral Vascular SurgeryCompletedNCT01662856Phase 3

  Sponsor listed in the registry: Instituto Grifols, S.A.

• Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Parenchymous Tissue Open SurgeriesCompletedNCT01754480Phase 3

  Sponsor listed in the registry: Instituto Grifols, S.A.

• Safety and Efficacy Study of Flebogamma 5% DIF IGIV in Pediatric SubjectsCompletedNCT00634569Phase 4

  Sponsor listed in the registry: Instituto Grifols, S.A.

• Use of Antithrombin in Cardiac Surgery With Cardiopulmonary BypassCompletedNCT00823082Phase 2

  Sponsor listed in the registry: Instituto Grifols, S.A.

• Efficacy and Safety of Plasma Exchange With 5% Albumin in Beta-amyloid Peptide Clearance in Cerebral Spinal FluidCompletedNCT00742417Phase 2

  Sponsor listed in the registry: Instituto Grifols, S.A.

• Efficacy and Safety of Niuliva® for the Prevention of Hepatitis B Virus Recurrence in Newly Orthotopic Liver Transplant RecipientsCompletedNCT01131065Phase 3

  Sponsor listed in the registry: Instituto Grifols, S.A.

• Clinical Trial in Patients Diagnosed With Immune Thrombocytopenic PurpuraCompletedNCT00699140Phase 3

  Sponsor listed in the registry: Instituto Grifols, S.A.

• Safety and Efficacy Study of Fibrin Sealant Grifols Evaluated as an Adjunct to HemostasisCompletedNCT00684047Phase 2/3

  Sponsor listed in the registry: Instituto Grifols, S.A.

• Efficacy and Safety of Intramuscular HBIG Grifols for the Prevention of Recurrence After Liver TransplantationCompletedNCT00895713Phase 2

  Sponsor listed in the registry: Instituto Grifols, S.A.

• Evaluation of Serum Levels and Pharmacokinetics of a New Hepatitis B Immune Globulin Following Liver TransplantationCompletedNCT00838071Phase 3

  Sponsor listed in the registry: Instituto Grifols, S.A.